Cathvision has announced the market release of ECGenius system version 3.4, introducing multiple software enhancements aimed at improving procedural workflow and physician usability across and between electrophysiology (EP) labs.
A press release from the company notes that specific features of this latest system version allow the physician to measure the validation period after ablation for tracking medication impact; view different signal components simultaneously to improve nearfield signal interpretation; and adjust visual displays to maximise structured event annotations.
US subscription-based customers will begin receiving the upgrade shortly, while the EU market rollout for the ECGenius system is planned to start later this quarter, Cathvision’s release also states.
“In alignment with its growth strategy, Cathvision announced updates to its board of directors with the appointment of independent director Wendy Dittmer,” said Mads Matthiesen, chief executive officer (CEO) of Cathvision. “Wendy held strategic partnership and innovation leadership roles at Philips, and brings decades of experience in analytic and medical device integration and commercialisation. Her appointment reflects Cathvision’s commitment to a strong governance foundation as the company scales its market presence and deepens clinical collaborations.”
